In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|March 18, 2013
Thermo Fisher Scientific Introduces Software, Instruments, and Consumables
Author(s)BioPharm International Editors
Thermo Fisher Scientific Inc. launched new software, instruments, consumables, and services for analytical applications at Pittcon 2013.
Advertisement
Thermo Scientific Chromeleon ver. 7.2 chromatography data systems software, supports Thermo Scientific mass spectrometers and allows instruments to be integrated on enterprise-wide networks.
The Thermo Scientific Nicolet iS50 spectrometer can be upgraded from a FT-IR system to multi-range device capable of ATR, Raman, and NIR analysis without manually changing components.
The Thermo Scientific Dionex UltiMate 3000 Biocompatible Rapid Separation (BioRS) system, combines ultra-high performance liquid chromatography (UHPLC) with a corrosion-resistant flow path that can withstand high salt or extreme pH conditions.
The Thermo Scientific Dionex GlycanPac AXH-1 HPLC column allows for better analysis of glycans.
The iCAP 7000 family of inductively coupled plasma-optical emission spectrometers (ICP-OES) feature a high-resolution charged injection device (CID) imager.
The Thermo Scientific PicoSpin-45 spectrometer is a miniature NMR spectrometer designed for applied analysis in laboratories of any size.
Unity Lab SmartCapture Asset Utilization Monitoring provides automated support, service and maintenance, regardless of the instrument manufacturer.
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
3
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
4
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
5